John Schmitt, co-founder of iXpressGenes, discusses their biotechnology company's simple biochemical blood test to find markers of pre-PTSD. The test aims to prevent post-traumatic stress disorder and trauma-induced disease. The company originated from Dr. Joe Ng's experience witnessing a traumatic event and recognizing the need for immunological research. The test detects dysregulation in the body caused by prolonged stress and inflammation, which can lead to anxiety, depression, and other comorbid diseases. Early detection and prevention can significantly reduce healthcare costs and improve overall well-being.
iXpressGenes has developed a simple biochemical blood test to detect markers of pre-PTSD and prevent post-traumatic stress disorder and trauma-induced disease.
The test detects dysregulation in the body caused by prolonged stress and inflammation, which can lead to anxiety, depression, and other comorbid diseases.
Early detection and prevention of trauma-related disorders can significantly reduce healthcare costs and improve overall well-being.
The test can be used as a tool for clinicians to monitor patients' health and provide personalized care.
Future versions of the test aim to provide more precise and individualized information about dysregulation and disease risk.
iXpressGenes, biotechnology, blood test, pre-PTSD, post-traumatic stress disorder, trauma-induced disease, stress, inflammation, dysregulation, anxiety, depression, comorbid diseases, early detection, prevention, healthcare costs
